Tideglusib

This page summarizes anecdotal reports and community observations, not medical evidence. Reports may be incomplete, biased or inaccurate and are not medical advice or recommendations. “Risk” here refers to how frequently severe or prolonged symptom worsening is reported, not to proven causation or population-wide probability. Individual responses vary widely, and absence of issues in some users does not rule out significant reactions in others.

Within PFS/PSSD/PAS communities, tideglusib is discussed in relation to its potential interactions with GSK-3β signaling pathways and downstream effects on neurosteroid biosynthesis, androgen receptor expression, neuroplasticity, and endocrine regulation. GSK-3β is a key enzyme involved in numerous cellular processes including neurogenesis, steroidogenesis, inflammation, and receptor signaling. Persistent symptoms after cessation of isotretinoin (Accutane) or finasteride are increasingly linked to long-term alterations in neurosteroid biosynthesis (e.g., reduced allopregnanolone), androgen receptor expression and signaling, BDNF (Brain-Derived Neurotrophic Factor) levels, myelination and neurogenesis, and hypothalamic–pituitary–gonadal axis regulation. All of these systems are modulated by GSK-3β. Chronic overactivity of this kinase has been associated with reduced neurosteroidogenesis, suppressed androgen signaling, mitochondrial dysfunction, impaired neuroplasticity, and HPA/HPG axis instability. Tideglusib's irreversible inhibition of GSK-3β may theoretically interact with pathways involving neurosteroid synthesis, androgen receptor signaling, BDNF expression, neurogenesis, or endocrine feedback mechanisms that are often discussed in relation to PFS / PSSD / PAS. The covalent binding mechanism means that even transient exposure can result in sustained inhibition until new enzyme synthesis occurs, which differs from reversible inhibitors like lithium that require sustained blood levels.

Experimental / High Risk

Tideglusib has been studied in clinical trials for neurodegenerative conditions and has demonstrated generally favorable safety profiles at standard doses (400–1000 mg/day), with the most common side effects being mild to moderate gastrointestinal discomfort, occasional headache or fatigue, and transient, reversible liver enzyme elevations at higher doses (≥500 mg/day). However, tideglusib remains an investigational compound that is not approved for general use, and no formal studies exist for PFS/PSSD/PAS-specific applications. Given the high-impact nature of GSK-3β inhibition and the theoretical complexity of its downstream effects, many view tideglusib as a high-complexity, experimental intervention that warrants careful consideration and medical oversight rather than casual experimentation.

Experimental. No Anecdotes.